Recent News Releases

• Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives • Company will utilize its combination of...

First orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan Partner Kissei to market TAVNEOS® in Japan, with launch expected as soon as...

CSL has remained agile to stay ahead of the pandemic challenges and has redirected resources to where it can add the most value to address the pandemic challenges. From the time the coronavirus...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Sparsentan is a potential first-in-class treatment to address significant unmet medical need in rare kidney disorders focal segmental glomerulosclerosis...

CSL confirms there was a positive COVID-19 case at its Broadmeadows manufacturing facility last week. All employees and contractors who were present at the same time as the confirmed case have...